Abacus Life, Inc. (ABL)
$
6.93
+0.02 (0.29%)
Key metrics
Financial statements
Free cash flow per share
-2.8878
Market cap
670.6 Million
Price to sales ratio
4.1464
Debt to equity
0.8596
Current ratio
0
Income quality
6.0470
Average inventory
0
ROE
-0.0030
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Abacus Life, Inc. operates as an alternative asset manager specializing in life insurance products. It purchases life insurance policies from consumers seeking liquidity and manages policies over time via trading, holding, and/or servicing. The company reported selling, general, and administrative expenses of $90,797,902.00 indicating its operational overhead costs. Additionally, the company reported depreciation and amortization expenses of $7,910,000.00 reflecting the wear and tear of its assets. The cost of revenue for the company is $11,372,000.00 showcasing its production and operational expenses. The operating income ratio is -0.01 indicating the company's operational profitability margin. Moreover, the company's stock is identified with the symbol 'ABL' in the market, making it recognizable among investors. The firm was founded in 2004 and is based in Orlando, Florida. In the investment landscape, the stock is affordable at $4.83 suitable for budget-conscious investors. However, the stock has a low average trading volume of 1,052,334.00 indicating lower market activity, which may affect liquidity. With a market capitalization of $670,578,678.00 the company is classified as a small-cap player. It is a key player in the Insurance - Life industry, contributing significantly to the overall market landscape, and it belongs to the Financial Services sector, driving innovation and growth. As such, Abacus Life, Inc. continues to navigate its niche within the financial markets, offering unique opportunities for those interested in its specialized products and services.
Is Abacus Life, Inc. (ABL) a good investment?
Investing in Abacus Life, Inc. (ABL) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is Abacus Life, Inc. (ABL)'s stock forecast?
Analysts predict Abacus Life, Inc. stock to fluctuate between $4.60 (low) and $10.95 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Abacus Life, Inc.'s market capitalization?
As of 2025-08-29, Abacus Life, Inc.'s market cap is $670,578,678, based on 96,764,600 outstanding shares.
How does Abacus Life, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Abacus Life, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Abacus Life, Inc. (ABL) stock?
To buy Abacus Life, Inc. (ABL) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ABL. Place an order (Market, Limit, etc.).
What is the best time to invest in Abacus Life, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Abacus Life, Inc. perform in the last earnings report?
Revenue: $111,924,000 | EPS: -$0.34 | Growth: -300%.
Where can I find Abacus Life, Inc.'s investor relations reports?
Visit https://abacuslife.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Abacus Life, Inc.?
You can explore historical data from here
What is the all-time high and low for Abacus Life, Inc. stock?
All-time high: $13.25 (2024-02-07) | All-time low: $4.60 (2025-06-27).
What are the key trends affecting Abacus Life, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
proactiveinvestors.com
Abacus Global Management (NASDAQ:ABL) earlier this week reported record financial results and raised its 2025 guidance. The company said it nearly doubled both revenue and adjusted net income year over year in 2024 and has continued its momentum into 2025.
globenewswire.com
If you purchased or acquired stock in Abacus and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
seekingalpha.com
Abacus Global Management, Inc. (NASDAQ:ABL ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Elena Plesco - Chief Capital Officer Jay J. Jackson - CEO, President & Chairman Robert F.
globenewswire.com
MONTRÉAL, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Dorel Industries Inc. (TSX: DII.B, DII.A) today announced that on August 7, 2025, it again amended its asset backed loan (ABL) facility and term loan facility whereby Dorel's lenders agreed to continue to forebear from enforcing their rights and exercising their remedies under both the ABL facility and term loan facility further to a default by Dorel relating to certain financial covenants. The initial forbearance period commenced on May 9, 2025 and has now been extended to the earlier of September 16, 2025 and the occurrence of any event of default, other than the current event of default, under the ABL facility or term loan facility. Dorel will receive access to US$20.0 million additional liquidity in three tranches under the ABL facility in order to finance new inventory and must continue to provide the lenders with additional reporting during the forbearance period. In addition, the total maximum availability under the ABL facility was decreased to US$150.0 million as part of the amendment. As at June 30, 2025, the total amount of borrowings outstanding under the ABL facility was approximately US$92.0 million.
globenewswire.com
SAN FRANCISCO, July 23, 2025 (GLOBE NEWSWIRE) -- Abacus Global Management, Inc. (NASDAQ: ABL) is under mounting pressure as its stock continues to slide, driven by a series of damning reports from Morpheus Research—a newly formed investigative group led by analysts who previously worked at the renowned Hindenburg Research. Despite Abacus's public denials and the announcement of a $20 million share repurchase program, investor confidence remains shaken, with shares now down more than 36% over the past month.
zacks.com
Abacus Life, Inc. (ABL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
globenewswire.com
SAN FRANCISCO, July 15, 2025 (GLOBE NEWSWIRE) -- Abacus Global Management, Inc. (NASDAQ: ABL) is under mounting pressure as its stock continues to slide, driven by a series of damning reports from Morpheus Research—a newly formed investigative group led by analysts who previously worked at the renowned Hindenburg Research. Despite Abacus's public denials and the announcement of a $20 million share repurchase program, investor confidence remains shaken, with shares now down more than 36% over the past month.
businesswire.com
HOUSTON--(BUSINESS WIRE)-- #DXPE--DXP Enterprises, Inc. (NASDAQ: DXPE) today announced that on July 1, 2025, DXP Enterprises, Inc. (the “Company”) entered into an Increase Agreement (the “Increase Agreement”) by and among the Company and certain of the Company's subsidiaries as borrowers, certain other subsidiaries of the Company as guarantors, pursuant to which the aggregate commitments under the Company's existing asset-based revolving credit facility (the “ABL Facility”) were increased by $50 millio.
globenewswire.com
SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- Abacus Global Management, Inc. (NASDAQ: ABL) is under mounting pressure as its stock continues to slide, driven by a series of damning reports from Morpheus Research—a newly formed investigative group led by analysts who previously worked at the renowned Hindenburg Research. Despite Abacus's public denials and the announcement of a $20 million share repurchase program, investor confidence remains shaken, with shares now down more than 36% over the past month.
globenewswire.com
SAN FRANCISCO, July 02, 2025 (GLOBE NEWSWIRE) -- Abacus Global Management, Inc. (NASDAQ: ABL) is under mounting pressure as its stock continues to slide, driven by a series of damning reports from Morpheus Research—a newly formed investigative group led by analysts who previously worked at the renowned Hindenburg Research. Despite Abacus's public denials and the announcement of a $20 million share repurchase program, investor confidence remains shaken, with shares now down more than 36% over the past month.
See all news
